CS
DTIL icon

Credit Suisse’s Precision BioSciences DTIL Stock Holding History

Credit Suisse’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,261
Closed -$45K – 3390
2022
Q4 		$45K Buy
+1,261
New +$49.8K ﹤0.01% 3416
2022
Q3 		– Sell
-1
Closed – – 4093
2022
Q2 		$0 Sell
1
-1,039
-100% -$61K ﹤0.01% 4015
2022
Q1 		$95K Buy
1,040
+69
+7% +$9.38K ﹤0.01% 3479
2021
Q4 		$216K Buy
971
+42
+5% +$11.7K ﹤0.01% 4245
2021
Q3 		$321K Buy
929
+221
+31% +$74.9K ﹤0.01% 4061
2021
Q2 		$265K Sell
708
-359
-34% -$108K ﹤0.01% 4166
2021
Q1 		$332K Sell
1,067
-1,390
-57% -$487K ﹤0.01% 3966
2020
Q4 		$614K Buy
2,457
+1,809
+279% +$443K ﹤0.01% 3684
2020
Q3 		$119K Buy
648
+204
+46% +$40.6K ﹤0.01% 3908
2020
Q2 		$111K Buy
+444
New +$97.2K ﹤0.01% 3827

Other funds holding DTIL

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse's DTIL Position: Q1 2023 in Review

Credit Suisse sold out of Precision BioSciences (DTIL) in Q1 2023, closing a stake of 1,261 shares — an estimated $45K sold.

Credit Suisse first reported a position in DTIL in Q2 2020 and held it in 10 quarters. The position peaked at $614K in Q4 2020. 86 funds tracked by Wall St. Rank hold DTIL as of Q1 2023.

  • Credit Suisse reported no remaining Precision BioSciences position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 1,261 Precision BioSciences shares in Q1 2023, an estimated $45K.
  • Credit Suisse first reported a position in Precision BioSciences in Q2 2020 and held it in 10 quarters.
  • Credit Suisse's Precision BioSciences position peaked at $614K in Q4 2020.
  • 86 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.